Browse DERL2

Summary
SymbolDERL2
Namederlin 2
Aliases F-LAN-1; FLANa; F-LANa; CGI-101; derlin-2; Der1-like domain family, member 2; DERtrin-2; carcinoma related; ......
Chromosomal Location17p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Multi-pass membrane protein
Domain -
Function

Functional component of endoplasmic reticulum-associated degradation (ERAD) for misfolded lumenal glycoproteins, but not that of misfolded nonglycoproteins. May act by forming a channel that allows the retrotranslocation of misfolded glycoproteins into the cytosol where they are ubiquitinated and degraded by the proteasome. May mediate the interaction between VCP and misfolded glycoproteins (PubMed:16186509, PubMed:16449189). May also be involved in endoplasmic reticulum stress-induced pre-emptive quality control, a mechanism that selectively attenuates the translocation of newly synthesized proteins into the endoplasmic reticulum and reroutes them to the cytosol for proteasomal degradation (PubMed:26565908). ; FUNCTION: (Microbial infection) In contrast to DERL1, it is not involved in the degradation of MHC class I heavy chains following infection by cytomegaloviruses.

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0001967 suckling behavior
GO:0006517 protein deglycosylation
GO:0006986 response to unfolded protein
GO:0007631 feeding behavior
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0010498 proteasomal protein catabolic process
GO:0016049 cell growth
GO:0030307 positive regulation of cell growth
GO:0030433 ER-associated ubiquitin-dependent protein catabolic process
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0030970 retrograde protein transport, ER to cytosol
GO:0032386 regulation of intracellular transport
GO:0032387 negative regulation of intracellular transport
GO:0032527 protein exit from endoplasmic reticulum
GO:0033157 regulation of intracellular protein transport
GO:0034620 cellular response to unfolded protein
GO:0034976 response to endoplasmic reticulum stress
GO:0035966 response to topologically incorrect protein
GO:0035967 cellular response to topologically incorrect protein
GO:0036503 ERAD pathway
GO:0036507 protein demannosylation
GO:0036508 protein alpha-1,2-demannosylation
GO:0042176 regulation of protein catabolic process
GO:0042177 negative regulation of protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0045927 positive regulation of growth
GO:0051051 negative regulation of transport
GO:0051224 negative regulation of protein transport
GO:0051705 multi-organism behavior
GO:0070861 regulation of protein exit from endoplasmic reticulum
GO:0070862 negative regulation of protein exit from endoplasmic reticulum
GO:0090317 negative regulation of intracellular protein transport
GO:1903513 endoplasmic reticulum to cytosol transport
GO:1903573 negative regulation of response to endoplasmic reticulum stress
GO:1903828 negative regulation of cellular protein localization
GO:1904152 regulation of retrograde protein transport, ER to cytosol
GO:1904153 negative regulation of retrograde protein transport, ER to cytosol
GO:1904292 regulation of ERAD pathway
GO:1904293 negative regulation of ERAD pathway
GO:1904380 endoplasmic reticulum mannose trimming
GO:1904950 negative regulation of establishment of protein localization
Molecular Function -
Cellular Component GO:0005769 early endosome
GO:0005770 late endosome
GO:0030176 integral component of endoplasmic reticulum membrane
GO:0031227 intrinsic component of endoplasmic reticulum membrane
GO:0044322 endoplasmic reticulum quality control compartment
> KEGG and Reactome Pathway
 
KEGG hsa04141 Protein processing in endoplasmic reticulum
Reactome R-HSA-5619084: ABC transporter disorders
R-HSA-382556: ABC-family proteins mediated transport
R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-901042: Calnexin/calreticulin cycle
R-HSA-5678895: Defective CFTR causes cystic fibrosis
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-5619115: Disorders of transmembrane transporters
R-HSA-901032: ER Quality Control Compartment (ERQC)
R-HSA-5358346: Hedgehog ligand biogenesis
R-HSA-5387390: Hh mutants abrogate ligand secretion
R-HSA-5362768: Hh mutants that don't undergo autocatalytic processing are degraded by ERAD
R-HSA-392499: Metabolism of proteins
R-HSA-532668: N-glycan trimming in the ER and Calnexin/Calreticulin cycle
R-HSA-597592: Post-translational protein modification
R-HSA-162582: Signal Transduction
R-HSA-5358351: Signaling by Hedgehog
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolDERL2
Namederlin 2
Aliases F-LAN-1; FLANa; F-LANa; CGI-101; derlin-2; Der1-like domain family, member 2; DERtrin-2; carcinoma related; ......
Chromosomal Location17p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DERL2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolDERL2
Namederlin 2
Aliases F-LAN-1; FLANa; F-LANa; CGI-101; derlin-2; Der1-like domain family, member 2; DERtrin-2; carcinoma related; ......
Chromosomal Location17p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DERL2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 2.39; FDR: 0.000150 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolDERL2
Namederlin 2
Aliases F-LAN-1; FLANa; F-LANa; CGI-101; derlin-2; Der1-like domain family, member 2; DERtrin-2; carcinoma related; ......
Chromosomal Location17p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DERL2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0590.757
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1550.948
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0080.996
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2930.368
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4220.722
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.140.935
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0620.875
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0011
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1680.92
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0960.959
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0030.999
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0340.587
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolDERL2
Namederlin 2
Aliases F-LAN-1; FLANa; F-LANa; CGI-101; derlin-2; Der1-like domain family, member 2; DERtrin-2; carcinoma related; ......
Chromosomal Location17p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DERL2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDERL2
Namederlin 2
Aliases F-LAN-1; FLANa; F-LANa; CGI-101; derlin-2; Der1-like domain family, member 2; DERtrin-2; carcinoma related; ......
Chromosomal Location17p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DERL2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DERL2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDERL2
Namederlin 2
Aliases F-LAN-1; FLANa; F-LANa; CGI-101; derlin-2; Der1-like domain family, member 2; DERtrin-2; carcinoma related; ......
Chromosomal Location17p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DERL2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDERL2
Namederlin 2
Aliases F-LAN-1; FLANa; F-LANa; CGI-101; derlin-2; Der1-like domain family, member 2; DERtrin-2; carcinoma related; ......
Chromosomal Location17p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DERL2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDERL2
Namederlin 2
Aliases F-LAN-1; FLANa; F-LANa; CGI-101; derlin-2; Der1-like domain family, member 2; DERtrin-2; carcinoma related; ......
Chromosomal Location17p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DERL2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDERL2
Namederlin 2
Aliases F-LAN-1; FLANa; F-LANa; CGI-101; derlin-2; Der1-like domain family, member 2; DERtrin-2; carcinoma related; ......
Chromosomal Location17p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DERL2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.